Molecular weight of hydroxyethyl starch: is there an effect on blood coagulation and pharmacokinetics? ‡ ‡Declaration of interest. This study was funded in part by B. Braun, of which MB and AF are employees and DS is a paid consultant. B. Braun has funded other research in this department in the past, as have other competitor companies.
Authors:
- N. DettoriNDN. Dettori
- P. FrascaroloPFP. Frascarolo
- M. BurkiMBM. Burki
- M. BollMBM. Boll
- A. FischAFA. Fisch
- T. BombeliTBT. Bombeli
- D.R. SpahnDSD.R. Spahn
- 1 May 2005
- journal article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 94 (5) , 569-576
Abstract
The development of hydroxyethyl starches (HES) with low impact on blood coagulation but higher volume effect compared with the currently used HES solutions is of clinical interest. We hypothesized that high molecular weight, low-substituted HES might possess these properties. Thirty pigs were infused with three different HES solutions (20 ml kg(-1)) with the same degree of molar substitution (0.42) but different molecular weights (130, 500 and 900 kDa). Serial blood samples were taken over 24 h and blood coagulation was assessed by Thromboelastograph analysis and analysis of plasma coagulation. In addition, plasma concentration and in vivo molecular weight were determined and pharmacokinetic data were computed based on a two-compartment model. Thromboelastograph analysis and plasma coagulation tests did not reveal a more pronounced alteration of blood coagulation with HES 500 and HES 900 compared with HES 130. In contrast, HES 500 and HES 900 had a greater area under the plasma concentration-time curve [1542 (142) g min litre(-1), P<0.001, 1701 (321) g min litre(-1), P<0.001] than HES 130 [1156 (223) g min litre(-1)] and alpha half life (t(alpha)(1/2)) was longer for HES 500 [53.8 (8.6) min, P<0.01] and HES 900 [57.1 (12.3) min, P<0.01] than for HES 130 [39.9 (10.7) min]. Beta half life (t(beta)(1/2)), however, was similar for all three types of HES [from 332 (100) to 381 (63) min]. In low-substituted HES, molecular weight is not a key factor in compromising blood coagulation. The longer initial intravascular persistence of high molecular weight low-substituted HES might result in a longer lasting volume effect.Keywords
This publication has 19 references indexed in Scilit:
- New Light on Intravascular Volume Replacement Regimens: What Did We Learn from the Past Three Years?Anesthesia & Analgesia, 2003
- Binding of Hydroxyethyl Starch Molecules to the Platelet SurfaceAnesthesia & Analgesia, 2003
- Thromboelastography: Another Point of ViewAnesthesia & Analgesia, 2001
- Analysis of Coagulation Changes Associated with Supraceliac Aortic Crossclamping Using ThromboelastographyJournal of Surgical Research, 2001
- Low- and Medium-molecular-weight Hydroxyethyl StarchesAnesthesiology, 2000
- Citrate Storage Affects Thrombelastograph®AnalysisAnesthesiology, 2000
- Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy VolunteersClinical Drug Investigation, 1998
- Pentastarch may cause fewer effects on coagulation than hetastarchTransfusion, 1988
- Determination of the molar substitution ratio of hydroxyethyl starches by gas chromatographyAnalytical Chemistry, 1983
- Determination of alkoxyl substitution in cellulose ethers by Zeisel gas chromatographyAnalytical Chemistry, 1979